Cargando…

Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)

Nifurtimox is a recommended treatment for Chagas disease, but data from treated children are limited. We investigated the efficacy, safety and tolerability of nifurtimox administered as divisible, dispersible 30 mg and 120 mg tablets in children with Chagas disease. In this blinded, controlled study...

Descripción completa

Detalles Bibliográficos
Autores principales: Altcheh, Jaime, Castro, Luis, Dib, Juan C., Grossmann, Ulrike, Huang, Erya, Moscatelli, Guillermo, Pinto Rocha, Jimy José, Ramírez, Teresa Estela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790535/
https://www.ncbi.nlm.nih.gov/pubmed/33412557
http://dx.doi.org/10.1371/journal.pntd.0008912
_version_ 1783633444920623104
author Altcheh, Jaime
Castro, Luis
Dib, Juan C.
Grossmann, Ulrike
Huang, Erya
Moscatelli, Guillermo
Pinto Rocha, Jimy José
Ramírez, Teresa Estela
author_facet Altcheh, Jaime
Castro, Luis
Dib, Juan C.
Grossmann, Ulrike
Huang, Erya
Moscatelli, Guillermo
Pinto Rocha, Jimy José
Ramírez, Teresa Estela
author_sort Altcheh, Jaime
collection PubMed
description Nifurtimox is a recommended treatment for Chagas disease, but data from treated children are limited. We investigated the efficacy, safety and tolerability of nifurtimox administered as divisible, dispersible 30 mg and 120 mg tablets in children with Chagas disease. In this blinded, controlled study conducted January 2016–July 2018, 330 patients aged <18 years from 25 medical centres across three South American countries were randomised 2:1 to nifurtimox 10–20 mg/kg/day (aged <12 years) or 8–10 mg/kg/day (aged ≥12 years) for 60 days (n = 219), or for 30 days plus placebo for 30 days (n = 111) (ClinicalTrials.gov NCT02625974). The primary outcome was anti-Trypanosoma cruzi serological response (negative seroconversion or seroreduction ≥20% in mean optical density from baseline determined by two conventional enzyme-linked immunosorbent assays) at 12 months in the 60-day treatment group versus historical placebo controls. Nifurtimox for 60 days achieved negative seroconversion (n = 10) and seroreduction (n = 62) in 72 patients (serological response 32.9%; 95% confidence interval [CI] 26.4%, 39.3%, of all treated patients), confirming superiority relative to the upper 95% CI of 16% for controls. In patients aged <8 months, 10/12 treated for 60 days (83.3%) and 5/7 treated for 30 days (71.4%) achieved negative seroconversion. Overall serological response was lower for 30-day than for 60-day nifurtimox (between-treatment difference 14.0% [95% CI 3.7%, 24.2%]). The frequency of T. cruzi-positive quantitative polymerase chain reactions decreased substantially from baseline levels (60-day regimen 53.4% versus 1.4%; 30-day regimen 51.4% versus 4.5%). Study drug-related treatment-emergent adverse events (TEAEs), which were observed in 62 patients (28.3%) treated for 60 days and 29 patients (26.1%) treated for 30 days, were generally mild or moderate and resolved without sequelae; 4.2% of all TEAEs led to nifurtimox discontinuation. Age- and weight-adjusted nifurtimox for 60 days achieved a serological response at 12 months post-treatment that was superior to historical placebo, was well tolerated and had a favourable safety profile in children with Chagas disease. Although, at 1 year serological follow-up, efficacy of the shorter nifurtimox treatment was not comparable to the 60-day treatment regimen for the overall study population, further long-term follow-up of the patients will provide important information about the progress of serological conversion in children treated with nifurtimox, as well as the potential efficacy difference between the two regimens over time.
format Online
Article
Text
id pubmed-7790535
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-77905352021-01-27 Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO) Altcheh, Jaime Castro, Luis Dib, Juan C. Grossmann, Ulrike Huang, Erya Moscatelli, Guillermo Pinto Rocha, Jimy José Ramírez, Teresa Estela PLoS Negl Trop Dis Research Article Nifurtimox is a recommended treatment for Chagas disease, but data from treated children are limited. We investigated the efficacy, safety and tolerability of nifurtimox administered as divisible, dispersible 30 mg and 120 mg tablets in children with Chagas disease. In this blinded, controlled study conducted January 2016–July 2018, 330 patients aged <18 years from 25 medical centres across three South American countries were randomised 2:1 to nifurtimox 10–20 mg/kg/day (aged <12 years) or 8–10 mg/kg/day (aged ≥12 years) for 60 days (n = 219), or for 30 days plus placebo for 30 days (n = 111) (ClinicalTrials.gov NCT02625974). The primary outcome was anti-Trypanosoma cruzi serological response (negative seroconversion or seroreduction ≥20% in mean optical density from baseline determined by two conventional enzyme-linked immunosorbent assays) at 12 months in the 60-day treatment group versus historical placebo controls. Nifurtimox for 60 days achieved negative seroconversion (n = 10) and seroreduction (n = 62) in 72 patients (serological response 32.9%; 95% confidence interval [CI] 26.4%, 39.3%, of all treated patients), confirming superiority relative to the upper 95% CI of 16% for controls. In patients aged <8 months, 10/12 treated for 60 days (83.3%) and 5/7 treated for 30 days (71.4%) achieved negative seroconversion. Overall serological response was lower for 30-day than for 60-day nifurtimox (between-treatment difference 14.0% [95% CI 3.7%, 24.2%]). The frequency of T. cruzi-positive quantitative polymerase chain reactions decreased substantially from baseline levels (60-day regimen 53.4% versus 1.4%; 30-day regimen 51.4% versus 4.5%). Study drug-related treatment-emergent adverse events (TEAEs), which were observed in 62 patients (28.3%) treated for 60 days and 29 patients (26.1%) treated for 30 days, were generally mild or moderate and resolved without sequelae; 4.2% of all TEAEs led to nifurtimox discontinuation. Age- and weight-adjusted nifurtimox for 60 days achieved a serological response at 12 months post-treatment that was superior to historical placebo, was well tolerated and had a favourable safety profile in children with Chagas disease. Although, at 1 year serological follow-up, efficacy of the shorter nifurtimox treatment was not comparable to the 60-day treatment regimen for the overall study population, further long-term follow-up of the patients will provide important information about the progress of serological conversion in children treated with nifurtimox, as well as the potential efficacy difference between the two regimens over time. Public Library of Science 2021-01-07 /pmc/articles/PMC7790535/ /pubmed/33412557 http://dx.doi.org/10.1371/journal.pntd.0008912 Text en © 2021 Altcheh et al http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Altcheh, Jaime
Castro, Luis
Dib, Juan C.
Grossmann, Ulrike
Huang, Erya
Moscatelli, Guillermo
Pinto Rocha, Jimy José
Ramírez, Teresa Estela
Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)
title Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)
title_full Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)
title_fullStr Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)
title_full_unstemmed Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)
title_short Prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with Chagas disease one year after treatment (CHICO)
title_sort prospective, historically controlled study to evaluate the efficacy and safety of a new paediatric formulation of nifurtimox in children aged 0 to 17 years with chagas disease one year after treatment (chico)
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7790535/
https://www.ncbi.nlm.nih.gov/pubmed/33412557
http://dx.doi.org/10.1371/journal.pntd.0008912
work_keys_str_mv AT altchehjaime prospectivehistoricallycontrolledstudytoevaluatetheefficacyandsafetyofanewpaediatricformulationofnifurtimoxinchildrenaged0to17yearswithchagasdiseaseoneyearaftertreatmentchico
AT castroluis prospectivehistoricallycontrolledstudytoevaluatetheefficacyandsafetyofanewpaediatricformulationofnifurtimoxinchildrenaged0to17yearswithchagasdiseaseoneyearaftertreatmentchico
AT dibjuanc prospectivehistoricallycontrolledstudytoevaluatetheefficacyandsafetyofanewpaediatricformulationofnifurtimoxinchildrenaged0to17yearswithchagasdiseaseoneyearaftertreatmentchico
AT grossmannulrike prospectivehistoricallycontrolledstudytoevaluatetheefficacyandsafetyofanewpaediatricformulationofnifurtimoxinchildrenaged0to17yearswithchagasdiseaseoneyearaftertreatmentchico
AT huangerya prospectivehistoricallycontrolledstudytoevaluatetheefficacyandsafetyofanewpaediatricformulationofnifurtimoxinchildrenaged0to17yearswithchagasdiseaseoneyearaftertreatmentchico
AT moscatelliguillermo prospectivehistoricallycontrolledstudytoevaluatetheefficacyandsafetyofanewpaediatricformulationofnifurtimoxinchildrenaged0to17yearswithchagasdiseaseoneyearaftertreatmentchico
AT pintorochajimyjose prospectivehistoricallycontrolledstudytoevaluatetheefficacyandsafetyofanewpaediatricformulationofnifurtimoxinchildrenaged0to17yearswithchagasdiseaseoneyearaftertreatmentchico
AT ramirezteresaestela prospectivehistoricallycontrolledstudytoevaluatetheefficacyandsafetyofanewpaediatricformulationofnifurtimoxinchildrenaged0to17yearswithchagasdiseaseoneyearaftertreatmentchico
AT prospectivehistoricallycontrolledstudytoevaluatetheefficacyandsafetyofanewpaediatricformulationofnifurtimoxinchildrenaged0to17yearswithchagasdiseaseoneyearaftertreatmentchico